Business
CEL-SCI Reports Fiscal Second Quarter 2026 Results
VIENNA, Va., May 18, 2026--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.
About this update from Cel-sci Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/d61fdb926402419ff09c190e5ae6fcdf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hHI5gESv0K_m5jISmQiVQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/d61fdb926402419ff09c190e5ae6fcdf","width":480,"height":240},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/I6KivwpoAPUugTzoazMPlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/d61fdb926402419ff09c190e5ae6fcdf","width":480,"height":240}},"lazy":false},{"type":"text","content":"On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"VIENNA, Va., May 18, 2026--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and clinical developments for Multikine (Leukocyte Interleukin, Injection)*.","length":290,"tagName":"p"},{"type":"text","content":""During the fiscal second quarter, we made significant progress advancing Multikine toward potential commercialization and regulatory approval in multiple markets," stated CEL-SCI CEO Geert Kersten. "Our strategic partnership with Amarox represents an important milestone for CEL-SCI, providing a pathway to potential early commercialization and revenue generation for Multikine in Saudi Arabia through the SFDA’s Breakthrough Medicine Designation process as well as potential market access in the GCC countries. At the same time, we are starting efforts to initiate p...